Prime Minister Justin Trudeau introduced the opening of a serious vaccine manufacturing plant in Toronto Thursday— a part of Canada’s efforts to construct up the home biomanufacturing sector within the aftermath of the COVID-19 pandemic.
The new Sanofi facility is the biggest in Canada and is predicted to considerably improve Canada’s home manufacturing of pediatric and grownup vaccines for whooping cough, diphtheria and tetanus.
During the COVID-19 pandemic, it grew to become clear that Canada’s home manufacturing capability was inadequate to answer the pandemic emergency, leaving Canada to depend on imported vaccines.
Sanofi, a worldwide biopharmaceutical firm, acquired $415 million from Canada and one other $55 million from the Ontario authorities, to construct a flu vaccine and pandemic preparedness plant at its Toronto campus by 2026.
The firm says that facility might be prepared in 2027.
Between May 2020 and April 2022, Canada promised greater than $1.3 billion for 12 new or expanded biomanufacturing crops to make vaccines and antibody therapies.
